


Figure 1
schematic representation of study design

Figure 2
p27-specific CD8 response




Figure 3

p27-specific cytotoxic activity detected in vivo

SUBSTITUTE SHEET (RULE 26)




Figure 4
antigen-specific CD4 T cell response




Figure 5A

serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done




Figure 5B

serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done






Figure 5C

serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done




serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 5D




serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 5E




serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 5F




serum cytokine response in groups immunized with the liposome-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 5G




serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6A




serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6B




serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6C




serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6D




serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6E



serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6F



serum cytokine response in groups immunized with the emulsion-based formulations without (-) or with various amounts of TLR7/8 ligands together with QS21 and MPL. * not done

Figure 6G